DOI: 10.32098/mltj.04.2022.01

Orthobiologic Injectables in the Ankle Joint: a Narrative Review

Authors

  • E. Y. Roh Division of PM&R and Sports Medicine, Department of Orthopaedic Surgery, Stanford University School of Medicine, Redwood City (CA), U.S.A.
  • M. S. Rana Division of PM&R and Sports Medicine, Department of Orthopaedic Surgery, Stanford University School of Medicine, Redwood City (CA), U.S.A.
  • K. C. McInnis Department of PM&R, Spaulding Rehabilitation Hospital, Harvard Medical School, Charlestown (MA), U.S.A.; Massachusetts General Hospital, Sports Medicine, Harvard Medical School, Boston (MA), U.S.A.
  • D. R. Bakal Division of PM&R and Sports Medicine, Department of Orthopaedic Surgery, Stanford University School of Medicine, Redwood City (CA), U.S.A.
  • H. Borgstrom Department of PM&R, Spaulding Rehabilitation Hospital, Harvard Medical School, Charlestown (MA), U.S.A.; Massachusetts General Hospital, Sports Medicine, Harvard Medical School, Boston (MA), U.S.A.
  • J. Borg-Stein Department of PM&R, Spaulding Rehabilitation Hospital, Harvard Medical School, Charlestown (MA), U.S.A.

puberoh@stanford.edu

Keywords

Adult stem cells, ankle osteoarthritis, hyaluronic acid, BMAC, mesenchymal stem cells, MFAT, platelet-rich plasma, talar osteochondral lesions

Abstract

Background. The ankle joint is a frequent site of injury and bone remodeling, and often requires cartilage repair. Studies have shown that growth factors and bioactive compounds have regenerative properties capable of promoting cartilage restoration. Hyaluronic acid (HA) and orthobiologics like platelet-rich plasma (PRP) and adult stem cells (ASCs) are particularly interesting as therapeutic solutions for ankle cartilage repair and have received considerable attention over the years.

Methods. We performed a literature review to summarize the clinical uses and outcomes of HA, PRP and ASCs as reparative interventions in osteochondral lesions (OCL) and osteoarthritis (OA) of the ankle, when used alone and post-surgically.

Results. In total, 50 studies were eligible and included in this review. HA was shown to be a safe treatment option with a low rate of adverse effects and overall clinical improvement for talar OCL when used alone and post-surgically. PRP was found to be superior to HA for talar OCL in non-surgical and post-surgical patients. Studies evaluating HA injections for ankle OA noted a general improvement in pain and function post-injection with minimal adverse reactions, though there is mixed data regarding the efficacy of PRP injections for ankle OA. High-level randomized controlled trials are lacking for the evaluation of ASCs in talar OCL and ankle OA, though limited research has found them to be safe and efficacious.

Conclusions. HA and orthobiologics can be considered for use as a pre-surgical treatment in ankle OCL and OA, or as a second-line treatment for patients who remain symptomatic after surgery. The safety profile and subjective improvement in clinical outcomes following orthobiologic treatments is promising, though requires additional investigation.

View the entire article

Downloads

This article was originally published by Edra S.p.A. and is made available here as part of the Muscles, Ligaments and Tendons Journal archive. Its inclusion in the current Journal archive does not alter the copyright, licensing, or reuse terms applicable at the time of its original publication.

Published

2022-12-31

How to Cite

1.
Roh EY, Rana MS, McInnis KC, Bakal DR, Borgstrom H, Borg-Stein J. Orthobiologic Injectables in the Ankle Joint: a Narrative Review. MLTJ [Internet]. 2022 Dec. 31 [cited 2026 Nov. 20];12(4). Available from: https://mltj.online/index.php/mltj/article/view/6659

Most read articles by the same author(s)